ReFilx™, is a regenerative filler matrix which provides breast cancer patients with a cosmetically superior and minimally-invasive solution for the permanent restoration of breast tissue defects following lumpectomy. This proprietary polymer platform technology is based on innovative research at the University of Toronto and the University Health Network specializing in the development of novel immunomodulatory polymers. Other key areas where this platform technology can be applied is medical device coatings and as drug delivery vehicles for controlled and targeted delivery of therapeutics.
Company:
ID:
1749Keywords:
Biomaterials , Cancer , Companies , Nanomaterials and Nanoparticles , Polymers , Tissue Engineering
Marilee Krinsky
Marilee Krinsky
Technology Commercialization Manager
Innovations & Partnerships Office (IPO)
(416) 978-2514
